What is the purpose of this trial?
This is an open-label, multi-center, Phase Ib clinical study of RO6895882, in combination with MPDL3280A, to investigate the safety, pharmacokinetics, and therapeutic activity in patients with locally advanced and/or metastatic CEA-positive solid tumors, whose disease has progressed on or who are intolerant to the standard of care therapy. Enrolled patients who continue treatment will be treated until loss of clinical benefit, unacceptable toxicities, or withdrawal of consent. The anticipated treatment period is 24 months for both RO6895882 and MPDL3280A and may be modified if emerging data suggest a benefit. The target sample size is 75 patients.
Start Date: 04/28/2016
End Date: 02/01/2018
Last Updated: 02/22/2018
Study HIC#: 1503015509